– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) – – 33%...
Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no...
7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy at 1 billion...
- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment...
Data on CD19/BCMA dual-targeting FasTCAR-T GC012F showed 100% overall response rate (ORR) and 66.7% 6-month complete response (CR) rate among...
– Data demonstrates Notable’s PPMP potential in selecting more active investigational pre-hematopoietic stem cell therapy drug combinations, as compared to...
“The Progression of Surgical Robotics: Introducing the SSi Mantra System” Video Presentation Now Available for Viewing FORT LAUDERDALE, FL, June...
SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced...
Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for EntrepreneurshipSAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE)...
Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism.Strong investigator enthusiasm and continued robust...
Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICMLLAUSANNE,...
SAN CARLOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 09, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;...
Ongoing Phase 1b Dose-Escalation Study of Single-Agent Treatment with RVU120 in Patients with AML or High-Risk MDS Shows Clinical Benefit and...
Media ReleaseCOPENHAGEN, Denmark; June 9, 2023, at 9:00am CEST Results from phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab in combination...
A single dose of KT-253 drives tumor regression and demonstrates differentiated pharmacology compared to small molecule inhibitor (SMI) in preclinical...
FREMONT, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Chronus Health, Inc., a disruptor in point-of-care diagnostics, today announced it has...
LOS ANGELES, June 08, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announces that it remains confident...
Expanded collaboration with Thermo Fisher Scientific combines the new Seer Proteograph™ XT Assay Kit with the new Thermo Scientific™ Orbitrap™...
SAN MATEO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel therapeutics targeting...